Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03687242 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal Hyperplasia
A Phase 2 study of Congenital Adrenal Hyperplasia and CAH - Congenital Adrenal Hyperplasia, sponsored by Spruce Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
- 8
- Study locations
NCT03687242: Completed Phase 2 study of Congenital Adrenal Hyperplasia and CAH - Congenital Adrenal Hyperplasia, sponsored by Spruce Biosciences.
NCT03687242 is a Phase 2 study of Congenital Adrenal Hyperplasia and CAH - Congenital Adrenal Hyperplasia that has completed, run by Spruce Biosciences. The registered enrollment target is 11 participants, below the 101-participant average among 8 other Congenital Adrenal Hyperplasia trials with a reported enrollment target (89% lower). The trial reports 8 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03687242, a Phase 2 study of Congenital Adrenal Hyperplasia and CAH - Congenital Adrenal Hyperplasia, has completed, sponsored by Spruce Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
- 8
- Study locations
Study Summary
This is a Phase 2 study of SPR001 for the treatment of classic CAH that will provide 12 weeks of open-label treatment to eligible subjects.
Primary Outcome
Incidence of treatment-emergent adverse events including any serious adverse events, dose-limiting toxicities, and adverse events leading to discontinuation of study drug.
Conditions Studied
Interventions
- DRUG SPR001
Study Locations (8)
California
- Spruce Biosciences Clinical Site - Orange
- Spruce Biosciences Clinical Site - San Diego
Georgia
- Spruce Biosciences Clinical Site - Atlanta
Indiana
- Spruce Biosciences Clinical Site - Indianapolis
Michigan
- Spruce Biosciences Clinical Site - Ann Arbor
Minnesota
- Spruce Biosciences Clinical Site - Minneapolis
Nevada
- Spruce Biosciences Clinical Site - Las Vegas
Pennsylvania
- Spruce Biosciences Clinical Site - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2018-09-06 |
| Est. Completion | 2019-08-09 |
| Phase | Phase 2 |
What the finished NCT03687242 record still lists
NCT03687242 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 101-participant average among 8 other Congenital Adrenal Hyperplasia trials with a reported enrollment target (89% lower).
The record links to 3 conditions, with Congenital Adrenal Hyperplasia appearing as the primary indexed condition, and to 1 intervention - of which SPR001 is the first listed.
NCT03687242 lists 8 locations in 7 states (California, Georgia, Indiana).
Frequently Asked Questions
What is clinical trial NCT03687242 about?
NCT03687242 is a clinical study titled "Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal Hyperplasia". This is a Phase 2 study of SPR001 for the treatment of classic CAH that will provide 12 weeks of open-label treatment to eligible subjects.
What is the current status of trial NCT03687242?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2018-09-06. Estimated completion is 2019-08-09.
What conditions does trial NCT03687242 study?
This clinical trial studies the following conditions: Congenital Adrenal Hyperplasia, CAH - Congenital Adrenal Hyperplasia, CAH - 21-Hydroxylase Deficiency.
What interventions are being tested in trial NCT03687242?
The interventions under investigation include: SPR001 (DRUG).
Who is sponsoring clinical trial NCT03687242?
This trial is sponsored by Spruce Biosciences, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03687242 being conducted?
This trial has 8 study locations across California, Georgia, Indiana, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Congenital Adrenal Hyperplasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03687242's enrollment target sits among peer trials
11 8th of 8 higher than 1 of 8 other Congenital Adrenal Hyperplasia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Congenital Adrenal Hyperplasia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)
RECRUITING · Phase 2
-
An Extension Study to Evaluate Safety and Efficacy in Participants Treated With CRN04894
RECRUITING · Phase 2
-
A Trial of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia
RECRUITING · Phase 1
-
A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia
RECRUITING · Phase 3
-
A Study of Gene Therapy for Classic Congenital Adrenal Hyperplasia (CAH)
ACTIVE NOT RECRUITING · Phase 1
-
Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI